From a trading perspective, the sclx stock price forecast indicates relative strength compared to peers, as RSI levels remain in healthy mid-range territory. This typically offers room for price appreciation without overbought conditions. The most important thing to take away is that analysts increased their loss per share estimates for this year. Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. The lack of change in the price target is puzzling in light of the downgrade but, with a serious decline expected this year, we wouldn't be surprised if investors were a bit wary of Scilex Holding. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Investors tracking the sclx stock price forecast should note the recent uptick in 50-day moving average, signaling potential bullish momentum in the biotech sector. Market sentiment, driven by new clinical trial updates, may boost near-term valuations.
